Get started
Author

Dennis O. Iyekegbe

Observed institution: Mayo Clinic
OpenAlex ID: A5008027976
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2015 · Jenny L. Pokorny, David Calligaris, et al. · Clinical Cancer Research · 90
Network Modeling Identifies Patient-specific Pathways in Glioblastoma
2016 · Nurcan Tuncbag, Pamela Milani, et al. · Scientific Reports · 31
PDF
Supplementary Methods and Legend from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S5 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S1 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S2 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S3 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S4 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Data from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Data from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S4 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S2 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S3 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S5 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Figure S1 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Supplementary Methods and Legend from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
2023 · Jenny L. Pokorny, David Calligaris, et al.
Abstract 2617: Preclinical efficacy of GNE-317, a dual PI3K/mTOR inhibitor, with or without bevacizumab in EGFR and/or PTEN-mutated glioblastoma multiforme
2014 · Terence T. Sio, Jenny L. Pokorny, et al. · Cancer Research
Works count: 17
Citation count: 121
H-index: 2
I10-index: 2
Year
Topic
Type